These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 31865042)

  • 1. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
    Rusan M; Andersen RF; Jakobsen A; Steffensen KD
    Eur J Cancer; 2020 Jan; 125():121-129. PubMed ID: 31865042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
    Steffensen KD; Adimi P; Jakobsen A
    Int J Gynecol Cancer; 2017 Nov; 27(9):1842-1849. PubMed ID: 28763368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
    Singh A; Gupta S; Badarukhiya JA; Sachan M
    Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy.
    Zhang N; Zheng H; Gao Y; Shu T; Wang H; Cai Y
    J Ovarian Res; 2024 Mar; 17(1):55. PubMed ID: 38444005
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Lin KK; Harrell MI; Oza AM; Oaknin A; Ray-Coquard I; Tinker AV; Helman E; Radke MR; Say C; Vo LT; Mann E; Isaacson JD; Maloney L; O'Malley DM; Chambers SK; Kaufmann SH; Scott CL; Konecny GE; Coleman RL; Sun JX; Giordano H; Brenton JD; Harding TC; McNeish IA; Swisher EM
    Cancer Discov; 2019 Feb; 9(2):210-219. PubMed ID: 30425037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    Kurnit KC; Coleman RL; Westin SN
    Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer.
    Faaborg L; Andersen RF; Waldstrøm M; Henriksen JR; Adimi P; Jakobsen A; Steffensen KD
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
    Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
    Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
    J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer.
    Kim YN; Shim Y; Seo J; Choi Z; Lee YJ; Shin S; Kim SW; Kim S; Choi JR; Lee JY; Lee ST
    Clin Cancer Res; 2023 Jul; 29(14):2725-2734. PubMed ID: 37067525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
    Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
    Gallotta V; Conte C; D'Indinosante M; Capoluongo E; Minucci A; De Rose AM; Ardito F; Giuliante F; Di Giorgio A; Zannoni GF; Fagotti A; Margreiter C; Scambia G; Ferrandina G
    Eur J Surg Oncol; 2019 Nov; 45(11):2096-2102. PubMed ID: 31227342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis.
    Taliento C; Morciano G; Nero C; Froyman W; Vizzielli G; Pavone M; Salvioli S; Tormen M; Fiorica F; Scutiero G; Scambia G; Giorgi C; Greco P; Pinton P
    Int J Gynecol Cancer; 2024 Jun; 34(6):906-918. PubMed ID: 38658022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
    Konecny GE; Kristeleit RS
    Br J Cancer; 2016 Nov; 115(10):1157-1173. PubMed ID: 27736844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rucaparib: a novel PARP inhibitor for
    Colombo I; Lheureux S; Oza AM
    Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
    Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.